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  Preserved outer retina in AIPL1 LCA 
Leber’s congenital amaurosis (LCA) is a group of heterogeneous disorders characterized by 
an early-onset rod-cone dystrophy and severe visual loss.  The estimated incidence of LCA is 
2 - 3 per 100,000 births, making it the commonest cause of inherited blindness in 
childhood.1  There have been several human clinical trials that have demonstrated the 
safety and efficacy of gene therapy in LCA type 2 (caused by RPE65 variants).2   One of the 
principal criteria for successful gene therapy of inherited retinal disorders is a degree of 
cellular preservation of the diseased retina, in order to allow for the potential of functional 
restoration.  In this regard, LCA type 4 is of particular interest.  LCA type 4 is caused by 
variants in the gene Aryl-hydrocarbon-interacting protein-like 1 (AIPL1), which plays a role in 
molecular chaperoning within photoreceptors.3   Although AIPL1 sequence variants are 
associated with a relatively severe LCA phenotype, recent electrophysiological findings 
suggest that there may be some preservation of retinal function in young children with 
AIPL1 mutations.4  Encouragingly, there have now been successful gene replacement 
interventions in AIPL1 animal models,5  thus lending support for a human clinical trial to be 
considered in AIPL1 LCA.  Given the very poor prognosis of severe and rapidly progressive 
visual loss of AIPL1 LCA, and, at least early in the disease, the possibility of preserved retinal 
function, we aimed to determine if there was an early window of opportunity during which 
patients might be suitable for a human treatment trial, by means of assessing high 
resolution retinal imaging and clinical data, in order to identify young patients who might 
have relatively preserved outer retinal structure that would potentially be amenable to 
intervention. 
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Methods 
Given that AIPL1 mutations are estimated to account for only about 5% of LCA, this would 
equate to an approximate incidence of 1 in a million births.  With such a rare disease, it was 
necessary to draw from an international pool of potential patients.  We collected data on 
molecularly confirmed AIPL1 patients including demographics, visual acuity, fundus 
examination findings, optical coherence tomography (OCT) findings and genotype, and 
analyzed this database to give us an impression of the known pool of AIPL1 patients and 
their defining characteristics.  In young patients where standard OCT imaging proved 
difficult or unsatisfactory, attempts were made where possible to obtain high resolution 
OCT images using hand-held OCT probes. 
 
Results 
We compiled data on 42 patients with molecularly confirmed AIPL1 mutations and a LCA4 
phenotype from 18 countries worldwide.  The age of these patients ranged from 0.5 to 43 
yrs old (median age 8 yrs), with 24 patients (57%) aged less than 10 yrs, and 10 patients 
(24%) aged less than 5 yrs old.  The modal visual acuity was perception of light (PL), which 
was found in 21 patients (50%), with a range of visual acuities from no perception of light 
(NPL) to LogMAR 0.90.  Posterior pole examination findings were available in 39 patients 
(93%).  There was a normal posterior pole appearance in 7 of these 39 patients (18%) (age 
range 0.5 - 5 yrs), with a further 18 patients (46%) having retinal pigmentary changes 
without macular atrophy, and 13 patients (33%) exhibiting macular atrophy.  One further 
patient had an epiretinal membrane (3%). The youngest patient with macular atrophy was 6 
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yrs old.  The commonest observed sequence variant was p.W278X(c.834G>A), which was 
found in at least one allele in 26 patients (62%), and in the homozygous state in 15 patients 
(36%) (Table). 
OCT images were obtained for 19 patients (45%).  The significant nystagmus and poor vision 
observed in this phenotype, along with the young age of some of the patients, posed 
considerable challenges to obtaining high quality foveal OCT scans.  Of these 19 patients, six 
(32%) had poor quality scans or scans that were not foveal.  Of the remaining 13 patients in 
whom good OCT images had been obtained, nine patients (69%) had no evidence of 
photoreceptor structure at the macula.  Four of these 13 patients who had good macular 
scans, had undergone imaging with hand-held OCT probes.  Promisingly, however, three of 
these 13 patients (23%) did demonstrate significant outer retinal structure, with relative 
preservation of the inner segment ellipsoid (ISe) layer and outer nuclear layer at the fovea, 
with one further patient (patient #41, 3 yrs old) demonstrating qualified evidence of a foveal 
ISe layer (Figure).  Three of these four patients (75%) were homozygous for the common 
AIPL1 mutation p.W278X(c.834G>A).  Of note, the three patients with clear evidence of a 
foveal ISe layer constituted the youngest in the cohort, each being only one year of age or 
younger.  A 4-month follow-up scan carried out on one of the 1-yr-old patients (patient #37) 
continued to demonstrate evidence of retained outer retinal structure.  
 
Discussion 
This study shows that there is promising evidence from high resolution OCT imaging that, in 
the very youngest AIPL1 LCA patients imaged, there is relative preservation of foveal outer 
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retinal structure.  To the best of these authors’ knowledge, the three youngest children in 
this cohort represent the youngest AIPL1 LCA patients in the literature to date that 
demonstrate foveal outer retinal structure, which might be amenable to gene therapy. It is 
also encouraging that the majority of the patients with preserved foveal outer retinal 
structure in this study harbored the most commonly observed severe sequence variant 
found in AIPL1 LCA; if these findings can be extrapolated, it may be that the majority of LCA 
AIPL1 patients still retain preserved foveal outer retinal structure when very young.   
Given the very poor visual prognosis of this condition, and the possibility of a therapeutic 
window which seems to exist both structurally and functionally, along with the success of 
recent animal and human trials in this and other forms of LCA, a human gene therapy based 
approach may be worthy of consideration in a small group of selected patients with 
preserved outer retinal structure in AIPL1 LCA.  The results of this study suggest that any 
intervention may need to be initiated in the first few years of life. 
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